LAVA Therapeutics (NASDAQ:LVTX – Get Free Report)‘s stock had its “market outperform” rating restated by stock analysts at JMP Securities in a report released on Wednesday, Benzinga reports. They currently have a $6.00 price objective on the stock. JMP Securities’ price objective suggests a potential upside of 220.86% from the company’s previous close.
Separately, HC Wainwright restated a “buy” rating and issued a $6.00 price target on shares of LAVA Therapeutics in a research report on Friday, June 28th.
View Our Latest Stock Analysis on LVTX
LAVA Therapeutics Trading Up 3.9 %
LAVA Therapeutics (NASDAQ:LVTX – Get Free Report) last issued its quarterly earnings results on Tuesday, August 20th. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.05. LAVA Therapeutics had a negative net margin of 228.02% and a negative return on equity of 51.90%. On average, equities analysts forecast that LAVA Therapeutics will post -1.27 EPS for the current fiscal year.
Hedge Funds Weigh In On LAVA Therapeutics
A hedge fund recently bought a new stake in LAVA Therapeutics stock. Pathway Financial Advisors LLC acquired a new position in LAVA Therapeutics (NASDAQ:LVTX – Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 14,000 shares of the company’s stock, valued at approximately $47,000.
About LAVA Therapeutics
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.
Featured Stories
- Five stocks we like better than LAVA Therapeutics
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Advance Auto Parts Eyes Long-Term Growth Despite Q2 Hurdles
- Why Invest in High-Yield Dividend Stocks?
- Toll Brothers Stock Up on Q3 Beat: Luxury Homes Drive Growth
- 3 Best Fintech Stocks for a Portfolio Boost
- 4 No-Brainer Stocks to Hold This Fall for Steady Gains
Receive News & Ratings for LAVA Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LAVA Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.